6 informa of the Evidence. Journal of Addictiive Diseases. 14 (3), 1995. • Cowan A., Lewis J. W., Buprenorphine: combatting drug abuse with a unique opioid. Wileii-Liss, New York, NY, 1995. • riminal Justice Institute, The Corrections Yearbook: Instant Answers to Key Questions in Corrections (New York: Criminal Justice Institute, 1995). • Dole, V.P. Implications of methadone maintenance for theories of narcotic addiction. Journal of the American Medical Association 260(20): 3025-3029. 1988. • Dole, V.P. and Joseph, H. Long term outcome of patients treated with methadone maintenance. Annals of the New York Academy of Science 311: 181-189. 1978. • Dole, V.P. and Nyswander, M.E. A medical treatment for diacetyl morphine (heroin) addiction: A clinical trial with methadone hydrochloride. Journal of the American Medical Association 193: 646650. 1965. • Doran C. M., Shanahan M., Mattick R.P., Ali R., White J., Bell J.: Buprenorphine versus methadone maintenance: a cost- effectiveness analysis. Drug and Alcohol Dependence 71: 295302. 2003. • Drougalis J.L.R., Bootman J. L., Larson L.N., Mc Ghan W.F. “Farmacoeconomia: lo stato dell’arte”. Edizione italiana a cura di Lucioni C., Centro Informazione Sanitaria (CIS), Milano, 1991. • Hartog J.and Tusen D.J. Valium use and abuse by metadone maintenance clients. International Journal of Addictions 22, 1987. • Harwood HJ, Hubbard RL, Collins JJ, Rachal JV: The cost of crime and the benefits of drug abuse treatment: a cost-benefit analysis using TOPS data. NIDA Res. Monogr. 86: 209-235, 1988. Institute of Medicine. Federal Regulation of Methadone Treatment, op. cit., 22. • Johnson R.E., Pharm D., Chutuape M.A., Ph.D., Strain E.C., Walsh S.L., Stitzer M.L., and Bigelow G.E.,”A comparison of levomethadyl SPECIALE 1° PREMIO MOLTENI PER LA TOSSICODIPENDENZA acetate, buprenorphine, and methadone for opioid dependence”. The New England Journal of Medicine. 18, 343. 2000. • Lowinson J.H., Marion I.J., Joseph H., Dole V.P. Methadone maintenance. In substance abuse: a comprehensive textbook. 1992. • Magura S., Siddiqi Q., Freeman R.C., and Lipton D.S., “Changes in Cocaine Use After Entry to Methadone Treatment,” in Cocaine, AIDS, and Intravenous Drug Use (New York: Haworth Press, 1991). • Mattick R.P., Breen C., Kimber J., Davoli M. “ Terapia con metadone a mantenimento paragonata con terapie che non utilizzano gli oppiacei o con terapie sostitutive per la dipendenza da oppiacei. Cochrane Drugs and Alcohol Group. 2002. • Mattick R.P., Kimber J., Breen C., Davoli M. “Buprenorfina a mantenimento paragonata con il placebo o con il metadone a mantenimento per la dipendenza da oppiacei”. Cochrane Drugs and Alcohol Group. 2002. • Mello N.K.,, Mendelson M.P., Bree M.P., Lukas S.E. Buprenorphine suppresses cocaine selfadministration by rhesus monkeys. Science 245: 859-862, 1989. Nutt DJ. Receptor pharmacology of buprenorphine. Res. Clin. Forums 19 (2): 9-15, 1997. • Payte J.T., Khuri E.T. Principles of Methadone dose determination. In State Methadone Treatment Guidelines. (Rockville, M.D., U.S. Department of Health Human Services), 1993. • Villiger JW. Binding of buprenorphine to opiate receptors. Neuropharmacol. 23 (3): 373-375, 1994. • Ward J., Mattick R.P., Hall W. Key issues in methadone maintenance treatment (Sydney, New South Wales University Press) 1992. • Weddington WW, Barry S.B. Changes in mood, craving, and sleep during short-term abstinence reported by male cocaina addicts. Arch. Gentile Psychiatry, 47: 861-868. 1990. Tab. 1 – Parametri ematologici dei pazienti trattati con metadone (0 = inizio follow-up, dopo 120 giorni e dopo 240 giorni); *P < 0,05
N. 3 - OTTOBRE 2004 Tab. 2 – Parametri ematologici dei pazienti trattati con buprenorfina (0 = inizio follow-up, dopo 120 giorni e dopo 240 giorni); *P < 0,05 7
Change language